Distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia.

肺泡 T 细胞反应的独特演变与未接种疫苗的 SARS-CoV-2 肺炎患者的临床结果相关

阅读:4
作者:Markov Nikolay S, Ren Ziyou, Senkow Karolina J, Grant Rogan A, Gao Catherine A, Malsin Elizabeth S, Sichizya Lango, Kihshen Hermon, Helmin Kathryn A, Jovisic Milica, Arnold Jason M, Pérez-Leonor Xóchitl G, Abdala-Valencia Hiam, Swaminathan Suchitra, Nwaezeapu Julu, Kang Mengjia, Rasmussen Luke, Ozer Egon A, Lorenzo-Redondo Ramon, Hultquist Judd F, Simons Lacy M, Rios-Guzman Estefany, Misharin Alexander V, Wunderink Richard G, Budinger G R Scott, Singer Benjamin D, Morales-Nebreda Luisa
The evolution of T cell molecular signatures in the distal lung of patients with severe pneumonia is understudied. Here, we analyzed T cell subsets in longitudinal bronchoalveolar lavage fluid samples from 273 patients with severe pneumonia, including unvaccinated patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with respiratory failure not linked to pneumonia. In patients with SARS-CoV-2 pneumonia, activation of interferon signaling pathways, low activation of the NF-κB pathway and preferential targeting of spike and nucleocapsid proteins early after intubation were associated with favorable outcomes, whereas loss of interferon signaling, activation of NF-κB-driven programs and specificity for the ORF1ab complex late in disease were associated with mortality. These results suggest that in patients with severe SARS-CoV-2 pneumonia, alveolar T cell interferon responses targeting structural SARS-CoV-2 proteins characterize individuals who recover, whereas responses against nonstructural proteins and activation of NF-κB are associated with poor outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。